Mikhail Eydelman - Feb 1, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, GEN COUNSEL & CORP SEC
Signature
Mikhail Eydelman, by /s/ Andrew Guggenhime, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Feb 1, 2024
Transactions value $
-$87,453
Form type
4
Date filed
2/5/2024, 05:39 PM
Previous filing
Jan 4, 2024
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $35.7K +1.67K +8.05% $21.41 22.4K Feb 1, 2024 Direct
transaction PCVX Common Stock Sale -$15.3K -212 -0.95% $72.22 22.2K Feb 1, 2024 Direct F1, F2
transaction PCVX Common Stock Sale -$46.7K -638 -2.88% $73.17 21.5K Feb 1, 2024 Direct F1, F3
transaction PCVX Common Stock Sale -$25.4K -343 -1.59% $74.11 21.2K Feb 1, 2024 Direct F1, F4
transaction PCVX Common Stock Sale -$35.7K -474 -2.24% $75.39 20.7K Feb 1, 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (Right to Buy) Options Exercise $0 -1.67K -0.86% $0.00 192K Feb 1, 2024 Common Stock 1.67K $21.41 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $71.69 to $72.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $72.695 to $73.67. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 The price reported is a weighted-average price. The shares were sold at prices ranging from $73.70 to $74.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 The price reported is a weighted-average price. The shares were sold at prices ranging from $75.01 to $75.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.